Home > Products > All > LEVOFLOXACIN Injection in 5% Dextrose*
Product Image
Please see full prescribing and safety information, including boxed warning, for LEVOFLOXACIN premix bags. LEVOFLOXACIN Package Insert premix bags and LEVOFLOXACIN Medication Guide premix bags

Available in:

  • 250 mg per 50 mL in 5% Dextrose premix bags
  • 500 mg per 100 mL in 5% Dextrose premix bags
  • 750 mg per 150 mL in 5% Dextrose premix bags

Benefits:

  • AP Rated
  • Preservative-free
  • DEHP-free
  • PVC-free
  • Not made with natural rubber latex

Downloads:

PreventIV

LEVOFLOXACIN Injection in 5% Dextrose*

Brand Name Equivalent: LEVAQUIN® (LEVAQUIN is a registered trademark of Daiichi Sankyo Company, Limited Corporation.)
Therapeutic Category: Critical Care

PreventIV Measures® Features:

  • Easy-to-read drug name and strengths printed on the bags and front and back of overwraps
  • Bar codes on the overwraps for ease of scanning
  • Unique label design to help products stand out on the shelf
  • Enhanced packaging and labeling designed to promote safety and help reduce the risk of medication errors
  • Ready-to-use premix bags facilitate adherence to USP
NDC
#25021		 Description Strength Fill
Volume 		Concentration Container
Size 		Closure Unit
of Sale
132-81 Premix Bag 250 mg 50 mL 5 mg per mL N/A N/A 24
132-82 Premix Bag 500 mg 100 mL 5 mg per mL N/A N/A 24
132-83 Premix Bag 750 mg 150 mL 5 mg per mL N/A N/A 24
WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS
See full prescribing information for complete boxed warning.
  • Fluoroquinolones, including LEVOFLOXACIN INJECTION in 5% dextrose, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together [see Warnings and Precautions (5.1)], including:
    • Tendinitis and tendon rupture [see Warnings and Precautions (5.2)]
    • Peripheral neuropathy [see Warnings and Precautions (5.3)
    • Central nervous system effects [see Warnings and Precautions (5.4)]
Discontinue LEVOFLOXACIN INJECTION immediately and avoid use of fluoroquinolones, including LEVOFLOXACIN INJECTION in 5% dextrose, in patients who experience any of these serious adverse reactions [see Warnings and Precautions (5.1)]
  • Fluoroquinolones, including LEVOFLOXACIN INJECTION in 5% dextrose, may exacerbate muscle weakness in patients with myasthenia gravis. Avoid LEVOFLOXACIN INJECTION in 5% dextrose in patients with a known history of myasthenia gravis [see Warnings and Precautions (5.5)].
  • Because fluoroquinolones, including LEVOFLOXACIN INJECTION in 5% dextrose, have been associated with serious adverse reactions [see Warnings and Precautions (5.1 to 5.14)], reserve LEVOFLOXACIN INJECTION in 5% dextrose for use in patients who have no alternative treatment options for the following indications:
    • Uncomplicated urinary tract infection [see Indications and Usage (1.12)]
    • Acute bacterial exacerbation of chronic bronchitis [see Indications and Usage (1.13)]
    • Acute bacterial sinusitis [see Indications and Usage (1.14)]